Neuhausen S L, Godwin A K, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo M A, Scott R J, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King M C, Ponder B A, Weber B, Devilee P, Borg A, Narod S A, Goldgar D
Department of Medical Informatics, University of Utah School of Medicine, Salt Lake City, Utah 84108, USA.
Am J Hum Genet. 1998 Jun;62(6):1381-8. doi: 10.1086/301885.
Several BRCA2 mutations are found to occur in geographically diverse breast and ovarian cancer families. To investigate both mutation origin and mutation-specific phenotypes due to BRCA2, we constructed a haplotype of 10 polymorphic short tandem-repeat (STR) markers flanking the BRCA2 locus, in a set of 111 breast or breast/ovarian cancer families selected for having one of nine recurrent BRCA2 mutations. Six of the individual mutations are estimated to have arisen 400-2,000 years ago. In particular, the 6174delT mutation, found in approximately 1% of individuals of Ashkenazi Jewish ancestry, was estimated to have arisen 29 generations ago (1-LOD support interval 22-38). This is substantially more recent than the estimated age of the BRCA1 185delAG mutation (46 generations), derived from our analogous study of BRCA1 mutations. In general, there was no evidence of multiple origins of identical BRCA2 mutations. Our study data were consistent with the previous report of a higher incidence of ovarian cancer in families with mutations in a 3.3-kb region of exon 11 (the ovarian cancer cluster region [OCCR]) (P=.10); but that higher incidence was not statistically significant. There was significant evidence that age at diagnosis of breast cancer varied by mutation (P<.001), although only 8% of the variance in age at diagnosis could be explained by the specific mutation, and there was no evidence of family-specific effects. When the age at diagnosis of the breast cancer cases was examined by OCCR, cases associated with mutations in the OCCR had a significantly older mean age at diagnosis than was seen in those outside this region (48 years vs. 42 years; P=.0005).
在地理分布广泛的乳腺癌和卵巢癌家族中发现了几种BRCA2突变。为了研究BRCA2突变的起源以及突变特异性表型,我们构建了一个单倍型,该单倍型包含位于BRCA2基因座两侧的10个多态性短串联重复序列(STR)标记,研究对象为111个乳腺癌或乳腺/卵巢癌家族,这些家族被选择是因为其中存在9种复发性BRCA2突变之一。据估计,其中6种个体突变出现在400 - 2000年前。特别是,在大约1%的阿什肯纳兹犹太血统个体中发现的6174delT突变,据估计出现在29代之前(1 - LOD支持区间为22 - 38)。这比我们对BRCA1突变进行类似研究所得出的BRCA1 185delAG突变的估计年龄(46代)要近得多。一般来说,没有证据表明相同的BRCA2突变有多个起源。我们的研究数据与之前的报告一致,即外显子11的3.3 kb区域(卵巢癌聚集区[OCCR])发生突变的家族中卵巢癌发病率较高(P = 0.10);但该较高发病率无统计学意义。有显著证据表明乳腺癌诊断年龄因突变而异(P < 0.001),尽管诊断年龄差异中只有8%可由特定突变解释,且没有家族特异性效应的证据。当按OCCR检查乳腺癌病例的诊断年龄时,与OCCR突变相关的病例诊断时的平均年龄显著高于该区域以外的病例(48岁对42岁;P = 0.0005)。